One of the most important clinical problems in lung cancer therapy is to improve the therapeutic strategy for patients with lung adenocarcinoma who develop epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) resistance. Here, EGFR is linked to lung cancer.